Company intelligence / Profile preview

FA212

Ownership: Private
Development stage: Other

Overview

FA212 is developing a gene therapy targeting the frataxin gene to treat Friedreich's Ataxia, aiming for innovation in vector manufacturing and regulatory reliability in partnership with Center for Breakthrough Medicines. No clinical results disclosed as of the latest report.

Therapeutic areas: Neurology
Modalities: Gene therapy
Industry: Biotech

Partnerships

Center for Breakthrough Medicines

Beyond the preview

Go deeper on FA212.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FA212.

Explore the full profile